Search Follow us

Threshold Pharmaceuticals (THLD)

Business description

Threshold is focused on tumour hypoxia, a low-oxygen condition found in most solid tumours and some blood cancers. Evofosfamide is in Ph III for STS and pancreatic cancer and earlier trials in other cancers. It is partnered with Merck KGaA.

Pivotal STS Phase III continues as planned

QuickView | Pharmaceutical & healthcare | 24/09/2014

The conclusion of the interim efficacy and safety analysis of Threshold’s ongoing Phase III soft tissue sarcoma (STS) trial is for the study to continue as planned, in line with both our and management’s expectations. Based on the current event rate, the number of events (n=434 deaths) required for the primary efficacy analysis are expected to be reached in H215. STS could be the first approved indication for TH-302.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.US$35.6m
Last closeUS$0.498
High / Low (52 weeks)US$1.3 / US$0.4
Stock market listingUS
Forecast net cash (US$m)31
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual26.6(1.2)(2.6)
Relative *24.2(4.6)(14.3)

* % Relative to local index

Company news